Loading
Pi3k/akt/mtor Signaling in Cancer / Colorectal Cancer Treatments and Studies / Genetic Factors in Colorectal Cancer · Journal article
Journal of Biological Research - Bollettino Della Società Italiana Di Biologia Sperimentale · September 8, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a small, single-centre molecular profiling study of 48 CRC cases from Kurdistan, Iraq, reporting unusually high NRAS (52.08%) and KRAS (47.92%) mutation frequencies and frequent co-mutations, alongside associations between inflammatory response and lymph node status with survival. The authors acknowledge the sample is small and call for larger cohorts and orthogonal validation, indicating these findings are exploratory and regional rather than definitive.
Retrospective molecular profiling study. 48 CRC cases from the Kurdistan region of Iraq; specific histopathological inclusion/exclusion criteria and stage distribution not provided.. Intervention: Molecular profiling for RAS and PI3K pathway mutations. n = 48. Kurdistan region of Iraq.
NRAS mutations were most frequently detected at 52.08%, followed by KRAS at 47.92% and PIK3CA at 16.67% High frequency of co-mutations, particularly involving KRAS and NRAS, substantially exceeding frequencies reported in international cohorts Tumor-associated inflammatory response and lymph node status demonstrated significant associations with patient survival
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
These findings suggest regional or population-specific differences in RAS pathway mutation profiles that may influence treatment selection (e.g. for EGFR inhibitors or targeted therapies). However, the small size and single-centre design mean clinicians should not yet alter practice based on this data; confirmation in larger, well-characterized cohorts using standardized methods is needed.
A small, single-centre molecular profiling study from an underrepresented population reporting mutation frequencies and survival associations, without a comparator arm or randomization, that the authors themselves flag as requiring larger validation.
As stated by the source record.
Quoted from the source exactly as published.
These findings suggest regional or population-specific differences in RAS pathway mutation profiles that may influence treatment selection (e.g. for EGFR inhibitors or targeted therapies). However, the small size and single-centre design mean clinicians should not yet alter practice based on this data; confirmation in larger, well-characterized cohorts using standardized methods is needed.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Mutations in RAS and PI3K pathway genes play a critical role in Colorectal Cancer (CRC) pathogenesis and therapy response, yet data from underrepresented populations remain limited. Molecular analysis was performed on 48 CRC cases from the Kurdistan region of Iraq to detect mutations in KRAS and NRAS (codons 12, 13, 59, 61, 117, and 146; exons 2–4), BRAF (codon 600; exon 15), PIK3CA (codons 542, 545, and 1047; exons 9 and 20), and AKT1 (codon 17; exon 4), and to correlate findings with histopathological characteristics and survival outcomes. NRAS mutations were the most frequently detected alterations (52.08%), followed by KRAS (47.92%) and PIK3CA (16.67%). A high frequency of co-mutations, particularly involving KRAS and NRAS, was observed, substantially exceeding frequencies reported in international cohorts; possible contributing factors including intratumoral heterogeneity and assay sensitivity are discussed. Tumor-associated inflammatory response and lymph node status demonstrated significant associations with patient survival. These findings from a small patient cohort suggest the need for further investigation of regional CRC molecular profiles using larger cohorts and orthogonal validation methods.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.